According to a new report Asia Pacific Genetic Testing Market, published by KBV research, the Asia Pacific Genetic Testing Market would witness market growth of 12.7% CAGR during the forecast period (2019-2025).
The China market dominated the Asia Pacific Molecular Testing Market by Country in 2018, growing at a CAGR of 10.2 % during the forecast period. The Japan market is expected to witness a CAGR of 13.5% during (2019 - 2025). Additionally, The India market is expected to witness a CAGR of 13.5% during (2019 - 2025).
The Diagnostic Testing market dominated the South Korea Genetic Testing Market by Type in 2018, growing at a CAGR of 12.9 % during the forecast period. The Prenatal and Newborn Testing market is expected to witness a CAGR of 12.9% during (2019 - 2025).
The Genetic Disease Diagnosis market dominated the Malaysia Genetic Testing Market by Application in 2018, growing at a CAGR of 13.7 % during the forecast period. The Cancer Diagnosis market is expected to witness a CAGR of 13.9% during (2019 - 2025).
Full Report:https://www.kbvresearch.com/asia-pacific-genetic-testing-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the mentioned countries. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Myriad Genetics, Inc., Empire Genomics LLC, Bio-Rad Laboratories, Inc., Novartis AG, Agilent Technologies, Inc., Thermo Fisher Scientific, Inc., Qiagen N.V., Illumina, Inc., Danaher Corporation, and Abbott Laboratories (Abbott Laboratories Molecular, Inc.).
By Type
By Technology
By Application
By Country
Companies Profiled
Unique Offerings from KBV Research
Unique Offerings 
